Less than one in 10 people who could benefit from GLP-1 drugs such as Wegovy can access them, caution the global health agency as it releases its inaugural advice on the therapies.
With in excess of 1,000,000,000 people worldwide currently living with obesity, it is urging increased and just availability to this class of drugs.
According to projections, in excess of 2,000,000,000 will be living with obesity by 2030 if no action is taken.
"The new guidelines acknowledges that excess weight is a long-term condition that can be addressed with thorough and continuous treatment," remarked its chief Tedros Adhanom Ghebreyesus.
Substantial prices, constrained manufacturing, and distribution challenges are key hurdles to broad availability to the jabs that can assist patients in reducing significant body mass, notes the body.
Skinny Jab Supply Crisis
Despite the current best projected outlook, the manufacturing of these medications might only reach around 100 million people – less than 10% of eligible patients, per the WHO.
The guideline calls on governments and firms to expand availability, by measures like voluntary licensing.
A patent on a key compound – the core component of a leading brand – is scheduled to end in multiple nations in 2026.
The Way Obesity Drugs Work
The injections imitate a body's own hormone to delay gastric emptying, curb appetite and boost satiety so people reduce food intake.
Individuals usually begin shedding pounds after several weeks of beginning the once-weekly jabs.
Studies suggests patients may see weight return a year later of discontinuing the medication, when their typical food cravings resume.
To be overweight or obese raises your chance for experiencing diseases, such as type 2 diabetes, heart disease, brain attack, and specific malignancies.
Obesity concerns people in every country and was responsible for millions of deaths worldwide in 2024, as per the WHO.
